


PREPARATION OF 2,9-DIOXABICYCLO[3.3.1]NONANES. A MODEL FOR TIRANDAMYCIN

Philip DeShong*, Subban Ramesh, Joseph J. Perez, Cynthia Bodish[†]

Department of Chemistry
The Pennsylvania State University
University Park, PA 16802

Summary: An efficient synthesis of a 2,9-dioxabicyclo[3.3.1]nonane system, similar to that of tirandamycin, is accomplished from 2,3-dimethylfuran.

Tirandamycin^{1,2} (1) is a member of the 3-acyl tetramic acid family of antibiotics which includes streptolydigin^{1,3}, nocamycin⁴, antibiotics Bu-2313 A and B⁵, ikarugamycin⁶, and others.⁷⁻⁹ It displays antibiotic activity¹⁰, as well as inhibitory activity against DNA-directed RNA polymerase.¹¹ These activities contrast sharply with those of simple 3-acyl tetramic acids and it has been proposed that the altered activity results from the presence of the 2,9-dioxabicyclo[3.3.1]nonane moiety found in these systems.¹



Ireland and co-workers have reported a synthesis of tirandamycinic acid (2), a degradation product of 1², in which the bicyclic ring system was prepared from D-glucose in a multistep scheme.¹² Recently, a second approach to the bicyclic system of tirandamycin has been reported by Ziegler and Thottathil which involves a furan precursor.¹³ This latter report has prompted us to report our preliminary results on a similar system. We have found that the 2,9-dioxabicyclo[3.3.1]non-7-ene-6-one system 3 can be efficiently prepared from 2,3-dimethylfuran (4) (see Scheme).



Lithiation of 2,3-dimethylfuran (4; ⁿBuLi, TMEDA, ether, R.T.) followed by condensation with THP ether-aldehyde 5^{15,16} gave furan-alcohol 6¹⁷, as a mixture of diastereomers, in 65% yield after flash chromatography. The ratio of diastereomers was approximately 27:16:15:42 based upon HPLC analysis. The diastereomers, although unstable to chromatography, could be purified by HPLC. Rather than separate the diastereomers (6) at this point however, it was advantageous to employ the mixture without purification.

Oxidation of 6 can be accomplished by a variety of reagents (PCC, 0°, 15',¹⁸; 1₀2, CH₃OH -20°¹⁹; m-CPBA, CH₂Cl₂, 0°, 30'²⁰; Br₂, CH₃OH, -20°, with or without added base, 15',²¹). Following oxidation treatment of the reaction mixture with 0.1N HCl in THF at R.T. gave bicyclic enone 3²² as a single isomer in 25% yield. Since 6 employed in the oxidation was a mixture of four diastereomers, oxidation-THP hydrolysis was expected to produce two intermediates 7 and 7'. Acid treatment of 7 would give bicyclic enone 3; similar treatment of 7' would result in the formation of 8. However, 8 was not detected. This result was not unexpected since 8 would carry three axial substituents on the six-membered ring - an unfavorable situation! It had been assumed that these conformational factors would preclude formation of 8 from 7'. In fact, a compound tentatively assigned the structure 10 (isolated as the acetate²³) could be obtained from the reaction mixture which had yielded 3. This product (10) did not give 3 upon resubjection to acid treatment, thus suggesting that it was the isomer (7') incapable of undergoing bicycle formation.


The low yield of 3 produced from the mixture of diastereomers (25%) was discouraging until it was determined that only the two highest Rf diastereomers of 6 - comprising ~43% of the mixture - could be converted into 3. The other two isomers gave 10 upon oxidation. Therefore, the overall yield of bicycle 3 from the furan bearing the correct stereochemistry at C-1' and C-3' in 6 was >60%.

The results presented in this report show that an appropriately substituted furan can effectively serve as the precursor to the enedione moiety found in tirandamycin. Secondly, they confirm that the stereochemistry at C-3' in 6 controls the ease of formation of the bicyclic enone system (7 → 3, but 7' → 8). A successful synthesis of tirandamycin via analogous methodology will require utilization of aldehyde 11, instead of 5, in which the C-2, C-3, C-4 stereochemistry of 11 will lead to the appropriate stereochemistry at C-3, C-4, C-5, and C-12 in 1. Studies related to the synthesis of optically active 11 and its utilization in the synthesis of tirandamycin will be reported in due course.

Acknowledgments. This research was partially supported by the NSF (URP #8025448). We acknowledge the assistance of Dr. Robert Minard (MS), Dr. Charles Debrosse (NMR) and Mr. Alan Freyer (NMR) in obtaining spectra. Partial support for the purchase of a Bruker WP-200 FT-NMR spectrometer by the NSF is gratefully acknowledged. Finally, we acknowledge valuable discussions with Dr. Steve Martin (Univ. of Texas).

1011

Scheme



References and Notes

‡ National Science Foundation Undergraduate Summer Research Participant, 1981.

1. Duchamp, D. J.; Branfman, A. R.; Button, A. C.; Rinehart, K. L., Jr. J. Amer. Chem. Soc. **1973**, 95, 4077; and references cited therein.
2. MacKellar, F. A.; Grostic, M. F.; Olson, E. C.; Wuuk, R. J.; Branfman, A. R.; Rinehart, K. L., Jr. ibid., **1971**, 93, 4943.
3. Rinehart, K. J., Jr.; Beck, J. R.; Borders, D. B.; Kinstle, T. H.; Krauss, D. ibid., **1963**, 85, 4038.
4. Horvath, G.; Brazhnikova, M. G.; Konstantinova, N. V.; Tolstykh, I. V.; Potapova, N. P. J. Antibiot. **1979**, 32, 555.
5. Nakagawa, S.; Naito, T.; Kawaguchi, H. Heterocycles **1979**, 13, 477.
6. Jamon, K.; Kuroda, Y.; Ajisaka, M.; Sakai, H. J. Antibiot. **1972**, 25, 271. Ito, S.; Hirata, Y. Tetrahedron Lett. **1972**, 1181. ibid. **1972**, 1185. ibid. **1972**, 2557.
7. Ballantine, J. A.; Ferrito, V.; Hassall, H.; Jones, V. I. P. J. Chem. Soc., C **1969**, 56.
8. Kunze, V.; Schabacher, K.; Zähler, H.; Zeeck, A. Arch. Microbiol. **1972**, 86, 147.
9. Schabacher, K.; Zeeck, A. Tetrahedron Lett. **1973**, 2691
10. Gyimesi, J.; Ott, I.; Horvath, I.; Koczka, I.; Maygar, K. J. Antibiot. **1971**, 24, 277. Horvath, G.; Gyimesi, J.; Méhesfalvi-Vajna, Z. Tetrahedron Lett. **1973**, 3643.
11. DeBoer, C.; Dietz, A.; Silver, W. W.; Savage, G. M. Antibiot. Annu. **1955-1956**, 886.
12. Meusser, C. E. J. Antibiot. **1971**, 24, 558.
13. Reusser, F. Infect. Immun. **1970**, 2, 77, and references cited therein.
14. Ireland, R. E.; Wutz, P. G. M.; Ernst, B. J. Amer. Chem. Soc. **1981**, 103, 3205.
15. Ziegler, F. E.; Thottathil, J. K. Tetrahedron Lett. **1981**, 22, 4883.
16. Rice, K. C.; Dyer, J. R., Jr. J. Heterocyclic Chem. **1975**, 12, 1325.
17. All compounds gave satisfactory analytical (IR, NMR, MS, elemental analysis) data.
18. Prepared by a slight modification of the reported procedure: Nicholau, K. C.; Pavia, M. R.; Seitz, S. P. J. Amer. Chem. Soc. **1981**, 103, 1224.
19. Furan-alcohol **6** (mixture of diastereomers): IR (neat): 3400, 3010 cm^{-1} . NMR (CDCl_3): δ 6.0 (s, 1H), 4.4-5.0 (m, 2H), 3.4-4.2 (m, 3H), 2.5-3.1 (m, 2H), 2.1-2.2 (series of singlets, 3H), 1.9 (series of singlets, 3H), 1.5-1.7 (m, 6H), 1.2 (series of doublets, 3H). Four diastereomers of **6** were detectable by tlc. First isomer (highest Rf): NMR (CDCl_3): δ 6.02 (s, 1H), 4.96 (s, 1H), 2.18 (s, 3H), 1.93 (s, 3H), 1.20 (d, J=7 Hz, 3H). Second isomer: NMR (CDCl_3): δ 6.02 (s, 1H), 5.00 (s, 1H), 2.20 (s, 3H), 1.96 (s, 3H), 1.23 (d, J=6 Hz, 3H). Third isomer: NMR (CDCl_3): δ 5.98 (s, 1H), 4.80 (s, 1H), 2.22 (s, 3H), 1.92 (s, 3H), 1.27 (d, J=6 Hz, 3H). Fourth isomer (lowest Rf): NMR (CDCl_3): δ 5.90 (s, 1H), 4.65 (s, 1H), 2.14 (s, 3H), 1.84 (s, 3H), 1.08 (d, J=7 Hz, 3H).
20. Piancatelli, G.; Scettri, A.; D'Auira, M. Tetrahedron **1980**, 36, 661.
21. Foote, C. S.; Mazur, S.; Burns, P. A.; Lerdal, D. J. Amer. Chem. Soc. **1973**, 95, 586.
22. Williams, P. D.; LeGoff, E. J. Org. Chem. **1981**, 46, 4143.
23. Clauson-Kaas, N.; Limborg, F.; Fakstorp, J. Acta Chim. Scand. **1948**, 2, 109.
24. Bicyclic enone **3**: IR (CCl_4): 2950, 1690 cm^{-1} . NMR (CDCl_3): δ 6.15 (broad s, 1H), 4.31 (dd, J=2, 7 Hz, 1H), 3.90 (m, 1H), 1.97 (d, J=1 Hz, 3H), 1.88 (m, 1H), 1.60 (m, 1H), 1.54 (s, 3H), 1.20 (d, J=6 Hz). Decoupling experiments confirmed the structure of the bicyclic enone as **3** and not the epimer **8**. ^{13}C NMR (CDCl_3): δ 197.3, 156.9, 126.9, 96.0, 75.0, 64.2, 34.1, 24.8, 21.9, 19.5.
25. **10**: 3500, 1685 cm^{-1} . Acetate of **10** (mixture of isomers): IR (CCl_4): 1740, 1680 cm^{-1} . Partial NMR (CDCl_3): δ 6.14 (broad s, 1H); 2.05 (s, 3H); 2.00 (broad s, 3H); 1.76 (s, 3H).

(Received in USA 19 January 1982)